China Approves Inhaled CanSino Covid-19 Vaccine For Clinical Trials
China’s drug authority has approved for clinical trials an inhaled Covid-19 vaccine co-developed by domestic firm CanSino Biologics, the company said in a filing on Tuesday.
This is coming after the National Medical Products Administration had given another CanSino vaccine a conditional approval last month for public use.
The vaccine for inhalation was jointly developed by CanSino Biologics and the Beijing Institute of Biotechnology.
China currently has five coronavirus vaccines but none of these are administered by inhalation.
AFP
Comments
Post a Comment